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ABSTRACT:
Benoxaprofen (BNX), a nonsteroidal anti-inflammatory drug
(NSAID) that was withdrawn because of hepatotoxicity, is more
toxic than its structural analog flunoxaprofen (FLX) in humans and
rats. Acyl glucuronides have been hypothesized to be reactive
metabolites and may be associated with toxicity. Both time- and
concentration-dependent glucuronidation and covalent binding of
BNX, FLX, and ibuprofen (IBP) were determined by exposing sand-
wich-cultured rat hepatocytes to each NSAID. The levels of gluc-
uronide and covalent protein adduct measured in cells followed
the order BNX > FLX > IBP. These results indicate that 1) BNX-
glucuronide (G) is more reactive than FLX-G, and 2) IBP-G is the
least reactive metabolite, which support previous in vivo studies in
rats. The proportional increases of protein adduct formation for
BNX, FLX, and IBP as acyl glucuronidation increased also support
the hypothesis that part of the covalent binding of all three NSAIDs
to hepatic proteins is acyl glucuronide-dependent. Moreover, the-
ses studies confirmed the feasibility of using sandwich-cultured
rat hepatocytes for studying glucuronidation and covalent binding
to hepatocellular proteins. These studies also showed that these in
vitro methods can be applied using human tissues for the study of
acyl glucuronide reactivity. More BNX-protein adduct was formed
in sandwich-cultured human hepatocytes than FLX-protein ad-
duct, which not only agreed with its relative toxicity in humans but
also was consistent with the in vitro findings using rat hepatocyte
cultures. These data support the use of sandwich-cultured human
hepatocytes as an in vitro screening model of acyl glucuronide
exposure and reactivity.
Many types of acidic drugs form acyl glucuronides, and other
xenobiotics are metabolized to carboxylic acids (Phase I metabolites),
which subsequently undergo Phase II conjugation to form acyl gluc-
uronides. Often such a glucuronide conjugate constitutes the major
metabolite. The major site of conjugation for most compounds in
humans is believed to be the liver. Modification of critical hepatic
proteins by covalent binding of acidic drugs through reactive acyl
glucuronides may provide a basis for direct hepatocyte toxicity or
immune-mediated adverse reactions (Gillette, 1974; Faed, 1984;
Boelsterli, 2002; Bailey and Dickinson, 2003).
Some pharmaceutical companies have been conducting in vitro
experiments by incubating acyl glucuronides with model proteins or
peptides (Wang et al., 2004) to determine their reactivity, and hence
possibly predict the relative extent of covalent protein binding in vivo
in humans. This method requires chemical synthesis or biosynthesis of
individual glucuronides for each drug candidate, a process that can be
tedious and costly. In addition, hepatic tissue proteins are not present
in the incubation, which makes it less likely to correlate covalent
protein binding with hepatotoxicity. In vitro models involving hepatic
materials, including liver homogenates, microsomal subcellular prep-
aration, and isolated hepatocyte suspensions and cultures, offer many
advantages over in vitro incubation with model proteins. Not only are
hepatic tissue proteins present, but UDP glucuronosyltransferase
(UGT) activities that catalyze the glucuronidation reactions are also
maintained. However, membrane transport functions are lost or not
well maintained in isolated hepatocytes or even primary hepatocyte
cultures. Although the intact animal model represents undisturbed
hepatic physiology, high-throughput screenings using in vivo studies
are not very practical. Moreover, extrapolation of animal data to
humans is often questionable, especially for drug metabolism.
We propose that hepatocyte culture with a “sandwich” configura-
tion would be a good model for estimating covalent binding to hepatic
tissue proteins in vivo. Hepatocyte monolayer is cultured between two
layers of Matrigel, a matrix material resembling the mammalian
cellular basement membrane, and this has been shown to prolong cell
viability and has better preservation of liver-specific protein synthesis
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than primary hepatocytes maintained under conventional culture con-
ditions (Dunn et al., 1989, 1991). This model system uses biologically
relevant matrix components and therefore is more close to the native
architecture of the hepatocyte environment. A unique feature of this
sandwiched culture of hepatocytes is the formation of functional bile
canalicular networks formed with rat hepatocytes. In addition, the
normal polarized distribution of several different classes of function-
ally active canalicular transport systems, such as multidrug-resistant
protein 2, is also re-established in this configuration (LeCluyse et al.,
1994). It has been reported that the hepatobiliary transport of reactive
diclofenac glucuronide via multidrug-resistant protein 2 is critical for
diclofenac covalent binding to proteins in the biliary tree (Seitz et al.,
1998). In addition to being a much more biologically relevant in vitro
model in terms of morphology and biochemical properties, this sand-
wiched hepatocyte culture system also maintains a better functional
enzyme/transport system than microsomes, with which the hepato-
cytes can generate metabolites such as acyl glucuronides. Further-
more, the availability of sandwiched human hepatocyte cultures will
allow in vitro evaluation of covalent binding in hepatocytes using
human tissues. This is essential for studies of compounds that are
potentially toxic to humans because direct detection of acyl gluc-
uronide-derived drug-protein adducts in human liver is not feasible.
Benoxaprofen (BNX) and flunoxaprofen (FLX), a pair of structural
analogs (Fig. 1) with different degrees of hepatotoxicity in humans
and rats, were selected as model compounds. BNX was marketed as
a racemic mixture, whereas FLX was marketed as the S-isomer only.
Several reports of fatal cholestatic jaundice, often associated with
nephrotoxicity, led to the withdrawal of BNX from the world market
only 5 months after its launch (Dahl and Ward, 1982). However, no
fatal adverse events related to FLX have been reported. We have
previously shown that BNX is more reactive than FLX with human
serum albumin and plasma protein in vitro, as well as in vivo in a rat
model (Dong et al., 2005). Fluorescent adducts of BNX and FLX have
also been detected with human plasma proteins from patients admin-
istered the drugs (Dahms and Spahn-Langguth, 1996). In this study,
we first evaluated the glucuronidation and protein adduct formation of
model compounds in the sandwiched rat hepatocyte culture. An in
vitro and in vivo correlation in rats in terms of relative reactivity of
glucuronide metabolites was then established. In addition, the effects
of modulating metabolism of BNX and FLX in vitro on the extent of
protein adduct formation were investigated. Finally, we examined the
applicability of sandwiched culture of human hepatocytes in estimat-
ing the relative covalent binding to hepatic proteins. Glucuronidation
and protein adduct formation of radiolabeled ibuprofen (IBP), a well
tolerated drug with a low incidence of side effects, in the sandwiched
rat hepatocyte culture were also determined and served as a reference.
These studies show through a series of experiments with rat hepato-
cytes the applicability of sandwich culture hepatocytes for investigat-
ing reactive acyl glucuronides and confirm that similar studies can be
conducted with human hepatocytes, thus allowing possible predictions
to humans.
Materials and Methods
Materials. Rac-BNX was extracted and purified from tablets of Oraflex
previously marketed by Eli Lilly & Co. (Indianapolis, IL). [Analysis calculated
for BNX (C16H12ClNO3): C, 63.69; H, 4.01; N, 4.64; Cl, 11.75; O, 15.91.
Found: C, 63.05; H, 4.31; N, 4.71; Cl, 11.68; O, 16.25.] The purity of BNX
(99%) was confirmed based on elemental analysis and analytical high-
performance liquid chromatography (HPLC) using UV detection at wave-
length of 210 nm. S-FLX, the marketed form, was contributed by Dr. A.
Forgione (Ravizza Laboratories, Milan, Italy) and was determined to be pure
(98%) based on HPLC with UV detection. IBP, Triton X-100, EDTA,
glycerol, glycine, phosphate-buffered saline (PBS), borneol, SKF-525A, lac-
tate dehydrogenase (LDH) kit, Percoll, Hanks’ balanced salt solution, and
dexamethasone were obtained from Sigma-Aldrich (St. Louis, MO). [3H]IBP
(1 Ci/mmol) was purchased from ICN (currently Valeant Pharmaceuticals,
Costa Mesa, CA). 1,7-Phenanthroline was purchased from Aldrich Chemical
Co. (Milwaukee, WI). 1-Aminobenzotriazole (ABT) was a gift from Dr. J.
Mathews at Triangle Research Institute (Research Triangle Park, NC). Proto-
gel, ammonium sulfate, TEMED, dithiothreitol, bromophenol blue, and Tris
were purchased from Bio-Rad Laboratories (Hercules, CA). Collagenase was
obtained from Worthington Biochemicals (Freehold, NJ). Dulbecco’s modified
Eagle’s medium (DMEM), modified Chee’s medium (MCM), fetal calf serum,
and insulin were purchased from Invitrogen (Carlsbad, CA). Rat tail collagen
(type I) was obtained from Collaborative Research (Bedford, MA). Matrigel
was purchased from Thermo Fisher Scientific (Waltham, MA). Methanol and
acetonitrile were HPLC grade from Mallinckrodt Baker, Inc. (Phillipsburg,
NJ). All of the other chemicals used were of reagent grade. Male Sprague-
Dawley rats (250–350 g) were supplied by Harlan (Indianapolis, IN). Exper-
iments were approved by the university’s animal care committee. Human liver
microsomal preparations were obtained from BD Gentest (Woburn, MA).
Isolation and Culture of Rat Hepatocytes. Plastic culture dishes (60 mm)
were precoated with rat tail collagen, type I (0.1 ml/dish, 1.5 mg/ml), in a
gelled state at least 1 day before hepatocyte harvest. To obtain a gelled
collagen substratum, neutralized collagen type I was prepared on ice (as
described by the manufacturer’s instruction) and spread onto Petri dishes with
a sterile Teflon (DuPont, Wilmington, DE) policeman. Freshly coated dishes
were then placed at 37°C in a humidified incubator for at least 60 min to allow
the matrix material to gel, followed by addition of 3 ml of fresh medium to the
dishes and storage in a humidified incubator until used. Just before cell
isolation, the medium was aspirated from the precoated culture dishes.
Hepatocytes were isolated from male Sprague-Dawley rats (250–350 g
b.wt.) by a modification of the two-step collagenase perfusion method as
previously described by LeCluyse et al. (1994) and Liu et al. (1999). Animal
studies were approved by the Institutional Animal Care and Use Committee at
the university. Rats were anesthetized with ketamine/acepromazine (75:2 mg/
kg, i.m.) before portal vein cannulation. The liver was perfused in situ with
oxygenated calcium-free buffer containing 5.5 mM glucose, 0.5 mM EDTA,
25.0 mM sodium bicarbonate, 1.2 mM potassium phosphate, pH 7.4, 4.7 mM
potassium chloride, and 118.0 mM sodium chloride for 10 min at 37°C,
followed by perfusion with buffer containing 2 mM calcium and collagenase
type II (0.3 mg/ml) for 10 to 15 min. After collagenase perfusion, the digested
liver was carefully removed and placed into a sterile, covered crystallization
dish and transported to a sterile hood, where 30 ml of DMEM kept at room
temperature and supplemented with 5% fetal calf serum, 1 M dexametha-
sone, and 4 mg/l insulin was immediately added. The hepatocytes were
dispersed by tearing open Glisson’s capsule with the aid of two sterile forceps
and gently shaking the liver until most of the cells were released into the
medium. The released cells were then filtered through a sterile nylon 70-m
filter into a 250-ml beaker. Another 30 ml of medium was added to the
crystallization dish, which was gently swirled to release any remaining cells
from the liver remnant, and filtered as before. This rinsing step was then
repeated one more time. The cell suspension was divided equally between two
50-ml sterile centrifuge tubes and centrifuged at 40g for 2 min at room
temperature. The supernatant fractions were discarded, and cell pellets were
gently resuspended in fresh DMEM to attain a final volume of 25 ml. An equal
volume of 90% isotonic Percoll (Percoll/10 Hanks’ balanced salt solution,
9:1, v/v) was added to the suspension, which was mixed well by inverting the
tube and centrifuged at 80g for 5 min at room temperature. The supernatant
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FIG. 1. Structures of BNX and FLX. BNX was marketed as the racemate; FLX was
marketed as the S-isomer.
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fraction was aspirated, and the cell pellets were resuspended in a combined
volume of 40 ml of medium and transferred into one 50-ml centrifuge tube.
The cells were washed again by centrifugation at 60g for 2 min. The final cell
pellet was resuspended gently in 40 ml of medium. Hepatocyte viability was
determined by trypan blue exclusion and was typically 90%. Cells were
diluted with fully supplemented medium to a cell concentration of 1.0  106
cells/ml, and 3-ml aliquots were seeded into 60-mm collagen-coated culture
dishes. After a 2-h attachment period at 37°C in a 5% CO2/95% air atmo-
sphere, the medium was replaced with fresh DMEM-supplemented insulin and
dexamethasone. The culture dishes were then placed in the 37°C humidified
incubator for 24 h until the Matrigel overlay (Fig. 2A shows the hepatocyte
morphology just before the overlay).
To prepare cultures in a sandwich configuration, the Matrigel stock solution
was slowly thawed at 4°C, diluted with ice-cold MCM to a final concentration
of 250 g/ml (Sidhu et al., 1993). The medium was aspirated from culture
dishes, and 3 ml of medium/Matrigel mixture was overlaid onto dishes with
precooled sterile pipettes. Matrigel-treated cultures were allowed to incubate
overnight. Medium was then changed daily until studies were performed. All
the experiments were done in 5-day postoverlay hepatocyte cultures (Fig. 2B)
and in serum-free MCM.
Studies with Rat Hepatocyte Culture. The glucuronidation and covalent
protein adduct formation in rat hepatocytes were first evaluated. For time
dependence studies, 500 M BNX, FLX, or IBP was dissolved in fresh MCM
and directly added to the rat hepatocyte cultures. The dose of 500 M IBP also
contained trace amounts of radiolabeled IBP (2.3 Ci of [3H]IBP/ml of culture
medium). After incubation for designated times, the cultures were extensively
washed with ice-cold PBS containing 0.2 mM phenylmethylsulfonyl fluoride
(PMSF) to reduce possible hydrolysis of acyl glucuronides by nonspecific
esterases. The cells were harvested in 2 ml of ice-cold PBS containing 0.2 mM
PMSF, 1% Triton X-100, and 10 l of 43% phosphoric acid and lysed by
Polytron (Kinematica, Littau-Lucerne, Switzerland). The cell homogenates
were then deproteinated by adding 4 ml of ice-cold acetonitrile (including 5 g
of internal standard) to precipitate proteins and extract unbound (not covalently
bound) drug and metabolites, followed by centrifugation at 4000 rpm for 10
min. The supernatant fractions and the protein pellets were stored at 80°C
until analyzed for the concentrations of acyl glucuronide and protein adduct
formed, respectively.
For concentration dependence studies, cultured rat hepatocytes were incu-
bated with various concentrations of BNX and FLX dissolved in MCM. BNX
reaches peak plasma concentrations greater than 100 M after oral doses of
600 mg to humans (Ridolfo et al., 1979), with higher concentrations expected
in liver during absorption; therefore, a range of up to 1000 M was selected
for these in vitro studies. After 6-h exposure, the cultures were extensively
washed with ice-cold PBS containing 0.2 mM PMSF, and the cells were
harvested as described above. Four milliliters of ice-cold acetonitrile (20 ng, 50
ng, 2 g, and 5 g of internal standard were added for concentrations of 10,
100, 250, and 500 M, respectively) was added to precipitate the proteins.
After the centrifugation of cell homogenates, the supernatant fractions and the
cell pellets were stored separately at 80°C. Cytotoxicity of BNX and FLX at
the highest concentration was estimated by determining LDH release into the
extracellular medium. LDH activities were determined spectrophotometrically
with a Sigma-Aldrich test kit. Enzyme activity in the medium was expressed
as percentage of total LDH present in the cells at the beginning of the
incubation.
The effects of modulating metabolic pathways on the glucuronidation and
covalent protein binding were determined. The cells were exposed to 500 M
BNX and FLX in the presence or absence of 1 mM borneol, 10 M SKF-
525A, or 1 mM ABT after preincubation with each for 30 min. Rat hepatocytes
were also pretreated with 200 M 1,7-phenathroline (PH) for 3 days (fresh
dose replaced daily), followed by the exposure of 500 M BNX and FLX.
Cells were also exposed to 500 M IBP (containing 2.3 Ci of [3H]IBP/ml of
culture medium) in the presence and absence of 1 mM borneol or 1 mM ABT
after preincubation with each for 30 min. All the incubations were carried out
to 6 h, at which time cells were extensively washed and harvested as described
above. Supernatant fractions and protein pellets separated by centrifugation
were stored at 80°C until further analysis.
HPLC analyses using the native fluorescence of BNX and FLX (details
described previously by Dong et al., 2005) were carried out to determine the
formation of BNX glucuronide (BNX-G) and FLX glucuronide (FLX-G) in the
rat hepatocytes. The supernatant fractions of harvested cells were evaporated
to dryness. The residues were reconstituted with 0.5 ml of mobile phase and
injected onto HPLC. For cells incubated with 10 and 100 M of either BNX
or FLX, 100 and 10 l of 0.5-ml reconstituted samples were injected, respec-
tively. For cells incubated with concentrations 250 M, additional dilution
of reconstituted samples was made before 20 l of the diluted samples was
injected onto HPLC.
For detection of IBP glucuronide (IBP-G) formed in the rat hepatocytes, an
HPLC assay (Castillo et al., 1995) was first carried out to isolate and collect the
IBP-G. The HPLC equipment used was essentially the same as for BNX and
FLX assays (Dong et al., 2005) but with a Hewlett-Packard (Palo Alto, CA)
variable wavelength detector (set at 250 nm) replacing the Shimadzu (Kyoto,
Japan) fluorescence detector. The mobile phase consisted of methanol/10 M
trifluoroacetic acid in water (60:40, v/v), and isocratic elution was performed
at a flow rate of 1.2 ml/min. The IBP-G peak was then collected with a fraction
collector, and the collections were evaporated to dryness under nitrogen.
Aliquots of 2.5 ml of 1 M sodium hydroxide were added to dissolve the
residues, which were then transferred into scintillation vials. Finally, 10 ml of
Ultima Gold scintillation fluid (PerkinElmer Life and Analytical Sciences,
Waltham, MA) was added, and the radioactivity was determined by liquid
scintillation counting.
Irreversible binding of BNX, FLX, and IBP metabolites to hepatocellular
proteins was determined as described previously (Dong et al., 2005). In brief, the
protein pellets were extensively washed with methanol/ether (3:1, v/v). After
centrifugation, the protein pellets were dried and incubated with 2.5 ml of 1 M
sodium hydroxide at 80°C for 1 h. BNX- and FLX-protein adducts were extracted
from sodium hydroxide with dichloromethane. The subsequently dried residues
were reconstituted in 250 l of proper mobile phase, and 200 l was injected onto
HPLC. IBP-protein adducts were determined by adding 10 ml of Ultima Gold
scintillation fluid (PerkinElmer Life and Analytical Sciences) to the sodium
hydroxide mixture. The total cell-associated radioactivity was determined by
liquid scintillation counting. Total protein content per dish was determined ac-
cording to Bradford (1976) using bovine serum albumin as standard protein.
Studies with Human Liver Microsomes and Human Hepatocyte Cul-
tures. Human liver microsomes from three subjects were used. The gluc-
uronidation of BNX and FLX in these preparations was measured similarly to
that described for rat liver microsomal studies by Dong et al. (1999). In brief,
microsomal protein was first incubated with Triton X-100 for 15 min at room
temperature. The incubation mixture (0.5 ml) contained 2 mg/ml microsomal
protein, 0.05% Triton X-100, 10 mM magnesium chloride, 100 mM Tris
buffer, pH 7.4, and 0.1 to 2 mM BNX or FLX with the addition of inhibitors
of hydrolytic enzymes (0.4 mM PMSF and 16 mM saccharic acid 1,4-lactone);
it was then warmed to 37°C for 5 min. The reaction (over a 20-min period) was
started by adding UDP-glucuronic acid (final concentration, 10 mM). Aliquots
of 0.10 ml were taken from the assay mixture at various times and were
pipetted into 0.20 ml of ice-cold acetonitrile (including internal standard). The
pH of the samples was adjusted to 2 to 4 to further stop the reaction. After
centrifugation, the supernatants were dried under nitrogen gas and reconsti-
tuted in 0.5 ml of mobile phase before injection onto the HPLC. Activities of
UGT are expressed as nanomoles of BNX-G or FLX-G formed per minute per
milligram of microsomal protein.
Kinetic analyses of UGT in the human liver were carried out by determining
initial rates of activity at five different fixed BNX and FLX concentrations
BA
FIG. 2. Hepatocyte cultures just before Matrigel overlay (A) or 5 days after overlay
in a sandwich configuration (B).
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(0.1, 0.2, 0.5, 1, and 2 mM). The initial glucuronide formation rate was
determined simply by using linear regression analysis on the BNX-G and
FLX-G formation over time profile. Kinetic constants (Vmax and KM) for UGT
were first estimated by plotting the initial rate of activity and substrate
concentration on double-reciprocal plots and Eadie-Hofstee plots, then deter-
mined by fitting the data to the Michaelis-Menten equation (WinNonlin 1.1;
Pharsight, Mountain View, CA).
Sandwiched human hepatocyte cultures (35-year-old white male, day 4
post-Matrigel overlay, five Petri dishes) were gifts from Dr. E. LeCluyse
(University of North Carolina at Chapel Hill, Chapel Hill, NC). BNX and FLX
dissolved in MCM at 500 M were added to the cell cultures (BNX, n  3;
FLX, n  2). After 6-h incubation, cell cultures were washed extensively, and
cells were harvested and lysed as described previously. The amounts of
BNX-G and FLX-G formed in the hepatocytes and the extent of covalent
binding of each to hepatic cellular proteins were determined as described
above.
Results
Time Dependence and Concentration Dependence of Gluc-
uronidation and Covalent Protein Binding in Rat Hepatocyte
Cultures. BNX- and FLX-induced hepatocyte injury was monitored
throughout the present study to ensure that glucuronidation and co-
valent protein binding of BNX and FLX were not compromised as a
result of acute cell injury. Exclusion of the vital dye trypan blue by the
hepatocyte cultures indicated that more than 85% of the cells were
still viable after treatment with various concentrations of BNX or FLX
for various periods. LDH release into the extracellular medium was
also measured as a marker for acute cell injury in the sandwich-
cultured rat hepatocytes. In the presence of 1000 M (the highest
concentration used in the present study) of BNX and FLX, LDH
leakage in the medium was not different from that in the control cells
for up to 12 h (data not shown). LDH release was increased after 24 h
to 24 and 18% of total LDH activity in BNX- and FLX-treated
hepatocytes, respectively, compared with 5% of total LDH leakage
in control cells. However, when the hepatocyte cultures were exposed
to 500 M BNX and FLX, no differences in LDH release were
observed between the treated and untreated cells (data not shown),
indicating that BNX and FLX treatment at the concentration of 500
M did not cause apparent cell injury.
Time-dependent glucuronidation of BNX, FLX, and IBP was de-
termined by exposing cultured hepatocytes to each at 500 M for up
to 24 h. BNX-G and FLX-G formed in the hepatocytes were quanti-
tated by HPLC-fluorescence analysis, whereas IBP-G was first iso-
lated by HPLC and then analyzed by liquid scintillation counting.
Formations of all three glucuronides were found to increase with time,
with the concentrations of BNX-G higher than FLX-G at any given
time, and IBP-G was detected at the lowest level (Fig. 3). Exposure of
cultured hepatocytes to BNX, FLX, and IBP was associated with the
appearance of drug irreversibly bound to hepatic proteins. Covalent
protein binding also accumulated over the incubation period, with the
highest protein adduct concentrations detected in BNX-treated hepa-
tocytes and the lowest in IBP-treated hepatocytes (Fig. 4). In addition,
covalent binding profiles appeared to mimic their corresponding glu-
curonidation profiles. In fact, covalent binding was found to increase
as a linear function of the acyl glucuronide concentrations (Fig. 5),
indicating that the covalent adduct formation may be mediated via
reactive acyl glucuronide. When normalized to glucuronide concen-
tration, the extent of adduct formation in the rat hepatocyte cultures
was highest after BNX treatment and the lowest after IBP, as indicated
by trends of the slopes of linear regressions of adduct versus gluc-
uronide concentration profiles in Fig. 5. This suggests that BNX-G is
the most reactive one among the three acyl glucuronides studied in
this study, and IBP-G is the least reactive acyl glucuronide of the three
examined here.
Concentration dependence of glucuronidation and protein adduct
formation of BNX and FLX ranging from 10 to 1000 M was
investigated at the 6-h incubation time. Nonlinear glucuronidation and
protein adduct formation were observed for both BNX and FLX at
concentrations higher than 100 M, and the maximal glucuronidation
and binding were reached at an initial concentration of 750 M (Figs.
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FIG. 3. Time-dependent glucuronidation profiles of BNX, FLX, and IBP in cul-
tured rat hepatocytes. Hepatocytes were exposed to 500 M BNX (f), FLX (F),
and IBP (Œ). At various times indicated, the cells were harvested, and the amounts
of glucuronides formed were determined. Values are mean  S.D. of triplicate
incubations.
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FIG. 4. Time-dependent covalent binding profiles of BNX, FLX, and IBP in cul-
tured rat hepatocytes. Hepatocytes were exposed to 500 M BNX (f), FLX (F),
and IBP (Œ). At various times indicated, the cells were harvested, and the concen-
trations of protein adducts formed were determined. Values are mean  S.D. of
triplicate incubations.
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6 and 7). Higher mean levels of BNX-G and BNX-protein adduct
were detected in the hepatocytes than FLX-G and FLX-protein ad-
duct, respectively, at all the concentrations examined.
Effects of Modulating Metabolism on the Covalent Protein
Binding. To assess whether covalent binding of BNX, FLX, and IBP
could be mediated via another metabolic pathway other than the
formation of reactive acyl glucuronides, the effects of modulating
glucuronidation (with borneol and PH) and oxidative metabolism
(with ABT and SKF-525A) on the covalent adduct formation were
examined. Borneol, which depletes glucuronidation cofactor UDP-
glucuronic acid (Watkins and Klaassen, 1983), almost completely
inhibited the formation of BNX-G, FLX-G, and IBP-G (Fig. 8). In
contrast, formation of adduct with BNX, FLX, and IBP to hepatocel-
lular proteins was only inhibited approximately half (46 and 50% for
BNX and FLX, respectively) in the hepatocyte cultures when treated
with borneol relative to control (Fig. 9). PH is a selective Phase II
enzyme inducer and has been shown to significantly increase BNX
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FIG. 6. Concentration-dependent glucuronidation of BNX and FLX in cultured rat
hepatocytes. BNX (f) and FLX (F) were added at the concentrations indicated.
After 6 h, the amounts of glucuronide formed in the cells were determined. Values
are the means  S.D. of triplicate incubations.
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FIG. 7. Concentration-dependent covalent binding of BNX and FLX in cultured rat
hepatocytes. BNX (f) and FLX (F) were added at the concentrations indicated.
After 6 h, the covalent protein adducts in the cells were determined. Values are the
means  S.D. of triplicate incubations.
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FIG. 8. Effects of UGT inhibitor and inducer on the glucuronidation of BNX, FLX,
or IBP in hepatocyte cultures. Hepatocyte cultures were incubated with 500 M
BNX, FLX, and IBP in the absence (control) or presence of 1 mM borneol or 200
M PH for 6 h. For induction study, cells were also preincubated with PH for 3
days. The zero time glucuronide values were subtracted from all the data. Values are
the mean  S.D. of triplicate incubations. Asterisks indicate significant difference
from the appropriate control (p  0.05). Note: 24-h incubation was conducted for
IBP, and the effect of PH on IBP glucuronidation was not studied.
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FIG. 5. Covalent protein binding of BNX (f), FLX (F), and IBP (Œ) correlate well
with their corresponding glucuronide formations in the rat hepatocyte cultures at
drug concentration of 500 M. Slopes of the linear regressions are 13.1, 10.1, and
9.76 for BNX, FLX, and IBP, respectively.
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glucuronidation in vivo in rats (Dong et al., 1999). In the present
study, we found that the glucuronidation of BNX and FLX was
significantly increased in hepatocyte cultures pretreated with PH (55
and 224% for BNX and FLX, respectively) compared with untreated
cultures (Fig. 8). However, no effect of PH on covalent protein
binding of either BNX or FLX was detected (Fig. 9). These data
suggest that the covalent protein binding of BNX, FLX, and IBP is
only partially mediated via the formation of reactive glucuronides.
An alternative metabolic pathway that may form reactive interme-
diate capable of binding covalently to proteins and releasing parent
drug when treated with base was then investigated. The effects of
inhibitors of cytochrome P450 (P450) activity on the glucuronidation
of BNX, FLX, and IBP were first evaluated to ascertain that the P450
inhibitors did not block the glucuronidation pathway. SKF-525A and
ABT, two general P450 inhibitors, did not appear to alter the gluc-
uronidation of BNX, FLX, and IBP (Fig. 10), nor did they reduce the
covalent bindings of drugs to cellular proteins (Fig. 11). These data
suggest that BNX, FLX, and IBP covalent protein adducts, as mea-
sured by base hydrolysis, are not likely to be mediated via the
formation of reactive oxidative metabolites.
Human UGT Activities in Liver Microsomes and Enzyme Ki-
netic Studies. The glucuronidation of BNX and FLX in human liver
microsomes from three different donors was determined over a range
of substrate concentrations. The dependence of the initial formation
rates of BNX-G and FLX-G as a function of the substrate concentra-
tion is illustrated in Fig. 12, with the maximum formation rates
reached at the substrate concentration of 1 mM. The extent of gluc-
uronidation varied dramatically between donors. The UGT activity of
donor 3 was very low; only a small amount of BNX-G was detected
in its liver microsomal preparation, and levels of FLX-G were below
the detection limit of the assay. Donors 1 and 2 appeared to have
similar formation rate versus substrate concentration profiles, with the
formation of BNX-G consistently faster than that of FLX-G. Michae-
lis-Menten parameters (Vmax and KM) were determined and summa-
rized in Table 1. The values of KM did not appear to differ between
BNX and FLX glucuronidation as a result of the high variability.
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FIG. 9. Effects of UGT inhibitor and inducer on the covalent binding of BNX, FLX,
and IBP to hepatocellular proteins. Hepatocyte cultures were incubated with 500
M BNX, FLX, or IBP in the absence (control) or presence of 1 mM borneol or 200
M PH for 6 h. For induction study, cells were also preincubated with PH for 3
days. The zero time binding values were subtracted from all the data but were
generally less than 5% of the values reported. Values are the mean  S.D. of
triplicate incubations. Asterisks indicate significant difference from the appropriate
control (p  0.05). Note: 24-h incubation was conducted for IBP, and the effect of
PH on IBP covalent protein binding was not studied.
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FIG. 10. Effects of P450 inhibitors on the glucuronidation of BNX, FLX, and IBP
in hepatocyte cultures. Hepatocyte cultures were incubated with 500 M BNX,
FLX, or IBP in the absence (control) or presence of 1 mM ABT or 10 M
SKF-525A for 6 h. The zero time glucuronide values were subtracted from all the
data. Values are the mean  S.D. of triplicate incubations. Note: 24-h incubation
was conducted for IBP, and the effect of SKF-525A on IBP glucuronidation was not
studied.
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FIG. 11. Effects of P450 inhibitors on the covalent binding of BNX, FLX, and IBP
to hepatocellular proteins. Hepatocyte cultures were incubated with 500 M BNX,
FLX, or IBP in the absence (control) or presence of 1 mM ABT or 10 M
SKF-525A for 6 h. The zero time binding values were subtracted from all the data.
Values are the mean  S.D. of triplicate incubations. Note: 24-h incubation was
conducted for IBP, and the effect of SKF-525A on IBP covalent protein binding was
not studied.
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Vmax, on the other hand, was higher for BNX glucuronidation in all
three microsomal preparations.
Glucuronidation and Covalent Protein Binding of BNX and
FLX in Human Hepatocyte Cultures. A pilot study was conducted
in five dishes of sandwiched human hepatocyte cultures from a single
donor. Both BNX-G and FLX-G were detected in the cells 6 h after
they were exposed to their parent drugs at 500 M, with the levels of
BNX-G significantly higher than FLX-G (Fig. 13). Greater amounts
of covalent binding to hepatocellular proteins were also detected in
the hepatocyte cultures exposed to BNX (Fig. 13). When adduct
formation was normalized to the glucuronide level, BNX-protein
adduct was still higher than FLX-protein adduct. This suggests that
BNX is more reactive than FLX in human hepatocyte cultures.
Discussion
The major site of glucuronidation for most compounds in humans
is believed to be the liver. Hepatotoxicity in elderly patients reported
for BNX was the cause of its withdrawal from the world market (Dahl
and Ward, 1982). The liver was also found to be a tissue targeted by
both BNX and FLX in vivo in rats (Dong et al., 2005). Therefore, an
in vitro model involving hepatic materials, such as intact cells or
slices, may be a better method for studying the acyl glucuronide-
derived drug-protein adducts than in vitro incubation with model
proteins. Hepatocyte cultures with a sandwich configuration were
selected in this study. Overlaying cultured hepatocytes with a top
layer of gelled collagen or Matrigel has been shown to prolong cell
viability and preserve liver-specific protein synthesis (Dunn et al.,
1989, 1991; Hewitt et al., 2007), which are more stable than micro-
somal incubations and allow for studies of time-dependent covalent
protein binding for up to 24 h. Furthermore, rat hepatocytes main-
tained in the sandwich configuration also re-establish a structural and
functional bile canalicular network that is usually fully developed
between 3 and 7 days after the overlay (LeCluyse et al., 1994). It has
been shown that the expression and function of primary active trans-
porters, such as the canalicular bile acid transporter and the canalic-
ular-multispecific organic anion transporters, were maintained in rat
sandwich-cultured hepatocytes for 96 to 120 h (Liu et al., 1999).
Therefore, cultures of rat hepatocytes at 5 days after Matrigel overlay
were used throughout the present study to ensure the functional
hepatobiliary transport of formed acyl glucuronides across canalicular
membrane. Drug uptake and enzyme-induction potential are also
better maintained in the sandwiched hepatocyte cultures (LeCluyse et
al., 1994; Hewitt et al., 2007), which makes manipulation of metabolic
pathways needed in the present study possible.
Three possible metabolic pathways that might lead to the covalent
binding to liver proteins have been proposed for carboxylic acids
(Skonberg et al., 2008), as exemplified by diclofenac, a popular model
compound for studies of liver protein adducts (Hargus et al., 1994).
The first pathway that involves the formation of reactive acyl gluc-
uronide has been shown to be responsible for covalent binding of
BNX, FLX, and IBP to serum albumin in vitro (Castillo and Smith,
1995; Dong et al., 2005) and to plasma and liver tissue proteins in
vivo in rat (Dong et al., 2005). Acyl glucuronides may bind covalently
to proteins by a transacylation mechanism and bind to the proteins via
Schiff base formation after acyl migration (Smith et al., 1990; Qiu et
al., 1998). The results of the present study have shown that acyl
glucuronide metabolites of BNX, FLX, and IBP are formed in rat
hepatocyte cultures and can bind covalently to hepatic proteins in a
time- and concentration-dependent manner (Figs. 3, 4, 6, and 7).
These results also indicate that BNX-G is more reactive than FLX-G
and IBP-G is the least reactive metabolite, which are in agreement
with both the in vitro studies with model proteins and the in vivo
studies in rats (Dong et al., 2005). The proportional increases of
adduct formation for BNX, FLX, and IBP as the glucuronidation
increases supported the hypothesis that some part of the covalent
binding of all three nonsteroidal anti-inflammatory drugs (NSAIDs) to
hepatic proteins is largely acyl glucuronide-dependent (Fig. 5). More-
over, it confirmed the feasibility of using sandwich-cultured rat hepa-
tocytes for studying glucuronidation and covalent binding to hepato-
cellular proteins. However, studies with the inhibitor and inducer of
glucuronide conjugation reaction indicate that the formation of reac-
tive acyl glucuronides may be only partially (50%) responsible for
the observed covalent binding of BNX, FLX, and IBP to hepatocel-
lular proteins in hepatocyte cultures (Figs. 8 and 9).
An alternative pathway for metabolic activation involving P450
was also investigated for its role in the covalent protein adduct
formation of BNX, FLX, and IBP in the rat hepatocytes. The reactive
metabolites of diclofenac and acetaminophen formed by P450 have
been reported to cause covalent modification of proteins (Hargus et
al., 1994). Studies on the metabolism and disposition of IBP have
shown that its major metabolites in plasma are carboxy- and hydroxy-
IBP (Mills et al., 1973), although 13% of the dose is excreted in urine
as IBP-G (Geisslinger et al., 1989). No oxidative metabolites have yet
been identified for BNX and FLX in either humans or animals.
However, our results of P450 inhibition studies suggested that BNX-,
FLX-, or IBP-protein adduct formation in vitro was not likely to be
mediated by oxidative metabolism (Figs. 10 and 11). Moreover, the
assay of adduct by cleavage with base to liberate parent drug is
unlikely to measure adducts formed by oxidative metabolism of BNX
or FLX.
A third pathway that is possible for the bioactivation of NSAIDs is
the formation of reactive acyl-CoA intermediate (Boelsterli, 2002;
Skonberg et al., 2008). Practically all the carboxylic acids are thought
to covalently modify proteins by this mechanism (Hertz and Bar-
Tana, 1988). This pathway may also lead to the inclusion of xenobi-
otic compounds in pathways of lipid biosynthesis (Tracy et al., 1993;
Dodds, 1995). Grillo and Benet (1996) first reported in abstract form
a tolmetin-glycine amino acid conjugate formed in vitro in freshly
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FIG. 12. The dependence of the initial rates of BNX-G (closed symbols) and
FLX-G (open symbols) formation with human liver microsomes as a function of
substrate concentrations. The liver microsomes were from three donors: donor 1
(Œ), donor 2 (), and donor 3 (f).
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isolated rat hepatocytes exposed to tolmetin. Their studies showed the
chemical reactivity of xenobiotic acyl-CoAs and their potential to
undergo nonenzymatic protein acylation. Sallustio et al. (2000) were
the first to show a direct relationship between xenobiotic-CoA for-
mation (in this case, nafenopin-CoA) and acylation of human liver
proteins. No acyl-CoA synthase-dependent BNX, FLX, or IBP adduct
formation was characterized in the present study because of a lack of
specific and potent inducers or inhibitors of this metabolic pathway.
However, formation of reactive NSAID-CoA intermediate may still
be responsible for part of the covalent binding of BNX and FLX to
hepatic proteins that are not accounted for by their reactive acyl
glucuronides (Figs. 8 and 9).
Once an in vitro and in vivo correlation of relative covalent protein
binding of BNX and FLX had been established using the rat as our
animal model, the applicability of using sandwiched human hepato-
cyte cultures to investigate the glucuronidation and drug-protein ad-
duct formation was examined. The preliminary studies showed that
the in vitro methods can be applied using human tissues. Greater
BNX-protein adduct was formed in human hepatocytes than FLX-
protein adduct (Fig. 13), which not only agreed with their relative
toxicity in humans but also was consistent with the findings in vitro
using rat hepatocyte cultures. However, the enzyme kinetic studies in
the small number of human liver microsomes suggested higher inter-
subject variability of UGT activity in humans (Fig. 12; Table 1) than
in inbred rats. With the exception of one donor who has very low UGT
activity, Vmax of BNX glucuronidation in humans (0.865 and 1.24
nmol/mg/min for donors 1 and 2, respectively) is higher than that in
rats (0.30  0.18 nmol/mg/min), whereas Km values are similar
in humans (0.322 and 0.396 mM for donors 1 and 2, respectively) and
in rats (0.52  0.43 mM). Further characterization is still needed
before sandwiched human hepatocyte cultures can be used as an in
vitro screening model of acyl glucuronide exposure and reactivity,
although the preliminary studies look promising and suggest the
method is transferable to human tissues.
In summary, the studies conducted and results obtained here show
the applicability of sandwiched hepatocyte culture for estimating
relative covalent binding of reactive acyl glucuronides in vivo and
validated the method as a useful in vitro/in vivo model. The formation
of labile and reactive acyl glucuronides was found to be at least partly
responsible for approximately half of the drug-protein adduct forma-
tion in the liver tissues in vitro. Whether covalent modification of
proteins in vivo leads to the observed hepatotoxicity of compounds,
such as BNX, is still uncertain because of a lack of animal hepato-
toxicity model for this and other drugs that form acyl glucuronides.
However, preliminary studies indicate that this in vitro method is
applicable to human tissue, which would provide a useful preclinical
screening method to rank-order relative reactivity of acyl glucuronide
metabolites of compounds containing carboxylic acid groups that are
candidates in drug discovery.
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